Measuring the success of treatment for chronic obstructive pulmonary disease--patient, physician and healthcare payer perspectives

Research output: Contribution to journalArticle

Standard

Measuring the success of treatment for chronic obstructive pulmonary disease--patient, physician and healthcare payer perspectives. / Van Der Molen, M; Pieters, W; Bellamy, D; Taylor, Rodney.

In: Respiratory Medicine, Vol. 96 Suppl C, 01.08.2002, p. S17-21.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{ab1491454fdb4f34a909be42fae533a2,
title = "Measuring the success of treatment for chronic obstructive pulmonary disease--patient, physician and healthcare payer perspectives",
abstract = "The success of treatments for chronic obstructive pulmonary disease (COPD) is evaluated by measuring the impact on a range of health outcomes. However, outcome measures differ in their relative importance to the various stakeholder groups. Patients are most interested in the impact on quality of life and on mortality, while physicians also value information about the effect of treatments on lung function and disease progression. In contrast to patients and physicians, healthcare payers take a population perspective, and need to balance the health gains achieved and the costs of treatment. If the management of COPD is to be improved, it is important, first, to understand the outcomes of importance to each relevant stakeholder group, and then second, to refocus the measures in terms that all stakeholders can value.",
author = "{Van Der Molen}, M and W Pieters and D Bellamy and Rodney Taylor",
year = "2002",
month = aug,
day = "1",
language = "English",
volume = "96 Suppl C",
pages = "S17--21",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Measuring the success of treatment for chronic obstructive pulmonary disease--patient, physician and healthcare payer perspectives

AU - Van Der Molen, M

AU - Pieters, W

AU - Bellamy, D

AU - Taylor, Rodney

PY - 2002/8/1

Y1 - 2002/8/1

N2 - The success of treatments for chronic obstructive pulmonary disease (COPD) is evaluated by measuring the impact on a range of health outcomes. However, outcome measures differ in their relative importance to the various stakeholder groups. Patients are most interested in the impact on quality of life and on mortality, while physicians also value information about the effect of treatments on lung function and disease progression. In contrast to patients and physicians, healthcare payers take a population perspective, and need to balance the health gains achieved and the costs of treatment. If the management of COPD is to be improved, it is important, first, to understand the outcomes of importance to each relevant stakeholder group, and then second, to refocus the measures in terms that all stakeholders can value.

AB - The success of treatments for chronic obstructive pulmonary disease (COPD) is evaluated by measuring the impact on a range of health outcomes. However, outcome measures differ in their relative importance to the various stakeholder groups. Patients are most interested in the impact on quality of life and on mortality, while physicians also value information about the effect of treatments on lung function and disease progression. In contrast to patients and physicians, healthcare payers take a population perspective, and need to balance the health gains achieved and the costs of treatment. If the management of COPD is to be improved, it is important, first, to understand the outcomes of importance to each relevant stakeholder group, and then second, to refocus the measures in terms that all stakeholders can value.

M3 - Article

C2 - 12199487

VL - 96 Suppl C

SP - S17-21

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -